Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $120.80 USD
Change Today 0.00 / 0.00%
Volume 0.0
AKBLF On Other Exchanges
As of 4:30 PM 08/10/15 All times are local (Market data is delayed by at least 15 minutes).

alk-abello a/s (AKBLF) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/6/15 - $121.20
52 Week Low
12/11/14 - $113.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ALK-ABELLO A/S (AKBLF)

Related News

No related news articles were found.

alk-abello a/s (AKBLF) Related Businessweek News

No Related Businessweek News Found

alk-abello a/s (AKBLF) Details

ALK-Abelló A/S, a pharmaceutical company, engages in the research and development, production, and sale of products for the diagnosis, prevention, and treatment of allergies worldwide. The company offers allergy immunotherapy products as injections, sublingual drops, and sublingual tablets for various allergies, including grass, ragweed, house dust mite, tree, cat, bee, and wasp. It also offers adrenaline auto-injectors for the treatment of severe allergic reactions. In addition, the company’s development programs include GRAZAX for grass allergic (ARC) and asthma prevention; GRASTEK for grass ARC; RAGWITEK for ragweed ARC; house dust mite (HDM) sublingual tablet-based allergy immunotherapy (SLIT)-tablets for HDM asthma and rhinitis; tree SLIT-tablet for tree ARC; and Japanese cedar SLIT-tablet for cedar tree ARC. It has strategic partnership agreements with Merck & Co., Inc. and Torii Pharmaceutical Co., Ltd. to develop, register, and commercialize SLIT-tablets in North America and Japan. The company was founded in 1923 and is headquartered in Hørsholm, Denmark.

1,833 Employees
Last Reported Date: 08/18/15
Founded in 1923

alk-abello a/s (AKBLF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

alk-abello a/s (AKBLF) Key Developments

ALK-Abelló A/S - Special Call

To review the label of the HDM SLIT-tablet

ALK-Abelló A/S Announces Earnings Results for the Second Quarter and First Half of 2015; Revises Earnings Guidance for the Year 2015

ALK-Abelló A/S announced earnings results for the second quarter and first half of 2015. For the quarter, the company continued to deliver underlying growth in its base business in line with that of the first quarter of 2015. Overall financial performance was impacted by lower milestone payments compared to last year: second quarter revenue, including partner income, amounted to DKK 565 million from DKK 615 a year ago. Second quarter revenue in the base business grew by 1% in local currencies to DKK 546 million from DKK 516 a year ago. Underlying growth was 4% when adjusted for last year's one-off upfront payment from ALK's collaboration partner for China. Second quarter partner income from SLIT-tablets was DKK 19 million against DKK 99 million, due to lower milestone payments. Second quarter EBITDA before special items was DKK 20 million against DKK 109 million a year ago. Excluding milestone payments and sales royalties, EBITDA before special items increased to DKK 19 million from DKK 10 million a year ago. For the first half period, the company’s first half total revenue was DKK 1,215 million against DKK 1,299 million a year ago and base business revenue growth was 3%. First half EBITDA before special items was DKK 158 million against DKK 320 million a year ago. Excluding sales royalties and milestone payments, EBITDA before special items grew to DKK 151 million against DKK 140 million a year ago, reflecting improved underlying profitability in the base business. For the year 2015, the full-year guidance has been adjusted to reflect the year-to-date sales growth in the base business and postponed investments: The company now expects to grow revenue in the base business by 3-5% in local currencies (previously 0-5%) based on low single-digit growth in Europe and high single-digit growth in non-European markets. Full-year revenue for the base business is expected to be DKK 2.3 billion to DKK 2.35 billion (previously DKK 2.25 billion to DKK 2.35 billion). The SLIT-tablet partnerships in North America and International markets are expected to generate additional revenue in the form of sales royalties, product supply, service fees and, potentially, milestone payments. Operating profit (EBITDA before special items), excluding sales royalties and milestone payments from partnerships, is expected to be in the range of DKK 250 million to DKK 300 million (previously DKK 225 million to DKK 300 million). Exchange rates are not expected to materially affect EBITDA. Free cash flow is projected to be negative in the range of DKK 50 million to DKK 150 million excluding sales royalties and milestone payments from partners (previously negative in the range of DKK 100 million to DKK 200 million). The company has strengthened its financial position through an increase of mortgage loans of net DKK 330 million.

ALK-Abelló A/S Presents at Goldman Sachs Annual Biotech and Emerging Pharma Symposium, Sep-11-2015

ALK-Abelló A/S Presents at Goldman Sachs Annual Biotech and Emerging Pharma Symposium, Sep-11-2015 . Venue: London, United Kingdom. Speakers: Per Plotnikof, Director of IR & Strategic Planning.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AKBLF:US $120.80 USD 0.00

AKBLF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AKBLF.
View Industry Companies

Industry Analysis


Industry Average

Valuation AKBLF Industry Range
Price/Earnings 41.6x
Price/Sales 3.2x
Price/Book 3.0x
Price/Cash Flow 38.8x
TEV/Sales 2.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALK-ABELLO A/S, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at